REDWOOD CITY, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a business update. "2022 is on track to be an important year for Adverum, as we progress our plan to initiate a Phase 2 trial evaluating two doses of ADVM-022 in patients with wet age-related macular degeneration," stated Laurent Fischer, M.D., president and chief executive officer at Adverum Biotechnologies.